-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gastric cancer is the fifth most common malignant tumor in the world and the third leading cause of cancer-related deaths
Gastric cancer is the fifth most common malignant tumor in the world and the third leading cause of cancer-related deaths
This article reviewed 227 patients with locally advanced gastric cancer (LAGC) who underwent NAC and subsequent radical gastric cancer surgery
This article reviewed 227 patients with locally advanced gastric cancer (LAGC) who underwent NAC and subsequent radical gastric cancer surgery
FLOT and SOX are commonly used research programs, accounting for 90%
There was no significant difference in the R0 resection rate between the two groups (90.
The median follow-up time was 31 months
The median follow-up time was 31 months
In the subgroup survival analysis, the three-drug treatment cohort did not show any advantages in any subgroup
In the subgroup survival analysis, the three-drug treatment cohort did not show any advantages in any subgroup
In summary, studies have shown that, compared with the two-drug regimen, the three-drug neoadjuvant treatment regimen does not bring additional survival benefits
In summary, studies have shown that, compared with the two-drug regimen, the three-drug neoadjuvant treatment regimen does not bring additional survival benefits
Original source:
Original source:Yonghe Chen, Jiasheng He, Dan Liu, et al.
Yonghe Chen, Jiasheng He, Dan Liu, et al.
Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis.
BMC Cancer (2021) 21:1328 https://doi.
org/10.
1186/s12885- 021-09093-9
Leave a message here
